Migraines could be tied to another common health problem – CBS News


CBS News

Migraines could be tied to another common health problem
CBS News
People with migraines and other headache disorders have a greater risk of a thyroid disease known as hypothyroidism, a new study suggests. Hypothyroidism occurs when the body doesn't produce sufficient amounts of thyroid hormone. This can cause ...
Migraine sufferers at a higher risk for thyroid diseaseBel Marra Health
Are your headaches linked to your thyroid?Health24

all 3 news articles »

Migraines could be tied to another common health problem – CBS News


CBS News

Migraines could be tied to another common health problem
CBS News
People with migraines and other headache disorders have a greater risk of a thyroid disease known as hypothyroidism, a new study suggests. Hypothyroidism occurs when the body doesn't produce sufficient amounts of thyroid hormone. This can cause ...
Migraine sufferers at a higher risk for thyroid diseaseBel Marra Health
Are your headaches linked to your thyroid?Health24

all 3 news articles »

Amgen (AMGN) Migraine Drug Hits Phase III Primary Endpoint – Yahoo Finance


Yahoo Finance

Amgen (AMGN) Migraine Drug Hits Phase III Primary Endpoint
Yahoo Finance
Amgen Inc. AMGN announced positive top-line data from a phase III study (ARISE) on calcitonin gene-related peptide (CGRP) receptor, erenumab (AMG 334), for the prevention of episodic migraine. The multi-center, randomized, 12-week, double-blind, ...
Novartis, Amgen chalk up PhIII migraine success to maintain lead over Lilly, TevaFierceBiotech
Novartis announces Phase III study shows AMG 334 significantly ...PharmiWeb.com (press release)
Amgen Maintains Migraine Drug Lead (AMGN)Investopedia
BioPharma Dive -PR Newswire (press release) -The Pharma Letter (registration)
all 21 news articles »

Alder BioPharma Could Lead The Migraine Market; Brean Assumes With Buy Rating – Benzinga


Benzinga

Alder BioPharma Could Lead The Migraine Market; Brean Assumes With Buy Rating
Benzinga
Alder Biopharmaceuticals Inc (NASDAQ: ALDR) is set to lead in the migraine market, at least according to Brean Capital, which has assumed coverage on the stock with a Buy rating and price target of $45. The company's lead product candidate, ALD403, ...
UPDATE: Brean Capital Assumes Alder Biopharm (ALDR) at BuyStreetInsider.com
Brokers Update Target Prices On Alder BioPharmaceuticals, Inc. (ALDR)Fiscal Standard

all 5 news articles »

Alder BioPharma Could Lead The Migraine Market; Brean Assumes With Buy Rating – Benzinga


Benzinga

Alder BioPharma Could Lead The Migraine Market; Brean Assumes With Buy Rating
Benzinga
Alder Biopharmaceuticals Inc (NASDAQ: ALDR) is set to lead in the migraine market, at least according to Brean Capital, which has assumed coverage on the stock with a Buy rating and price target of $45. The company's lead product candidate, ALD403, ...
UPDATE: Brean Capital Assumes Alder Biopharm (ALDR) at BuyStreetInsider.com

all 6 news articles »

Help for Migraine Suffers